CD274 and neoplasm: Another combination therapy study was the JAVELIN Renal 101 trial comparing axitinib plus avelumab, an anti-PDL1 antibody, with sunitinib in first-line metastatic RCCs: the treatment with axitinib plus avelumab increased the median PFS compared to subitinib (13.8 months vs. 8.4 months); tumor PD-L1 positivity did not modify progression-free survival or the overall response rate; the safety profile was comparable in the two arms of treatment [233].